Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...
In the final part of her conversation with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why her ...
Claude is being positioned as an enterprise “intelligence layer,” moving beyond chatbots toward agentic systems embedded in regulated drug development and operational workflows with auditability and ...
In April, FDA announced plans for a pilot program to allow for real-time data review during clinical trials. 1 The program ...
In April, FDA announced plans for a pilot program to allow for real-time data review during clinical trials. 1 The program ...
Violet’s seed extension supports IND-enabling studies of an EphB3 inhibitor to modulate microglia–astrocyte crosstalk and promote glial-mediated synaptic preservation in Alzheimer’s disease. Full-Life ...
Makary’s departure followed internal disputes over approval decisions and Covid-19 vaccine posture, catalyzing a rapid ...
Mike Petroutsas, president and head of U.S. commercial at Astellas, explores the importance of insight-driven ...
Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class ...
Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials. In April, ...
Aldosterone synthase inhibition targets upstream aldosterone production, differentiating baxdrostat from mineralocorticoid ...
In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results